/* */ PELVIPHARM - Preclinical outsourcing CRO in sexual dysfunction (ED, FSD,PE), cardiovascular & diabetes pharmacology & urology (overactive bladder, bph, detrusor overactivity, interstitial cystitis/Painful bladder syndrome, urinary incontinence).
Receive our news


Founded in 1999, PELVIPHARM is a spin-off from the University of Versailles-Saint-Quentin-en-Yvelines (France) relying on multi-disciplinary talents (medical doctor, pharmaco-economist, veterinarian, pharmacists and PhDs) who deliver both high quality academic standards and reliable contract research services :

  • Preclinical studies based on validated efficacy models including delivery of protocol development, study conduct, report, communication and peer-reviewed publication
  • Guidance for selection of new chemical entities including testing with targeted assays according to potential mechanisms of action
  • Identification of new properties or attributes supporting differentiation of medications within the class or between classes
  • Advice in clinical development for new therapeutic indications or enhancements to address unmet medical need or significant commercial opportunities

PELVIPHARM has leading scientific and medical capabilities from unique expertise and experience in pathophysiology, pharmacology, clinical research and medical practice across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC …), sexual medicine (ED, PE, FSD …) and cardiovascular (Hypertension, Atherosclerosis, Myocardial Infarction …), metabolism and eating disorders (Metabolic Syndrome, Obesity, Diabetes ...)

Cardiovascular fucntion Lower urinary tract Male and female sexual function

PELVIPHARM provides customized services to clients according to their outsourcing needs, using experimental models based on the most recent exploration methods.

PELVIPHARM can give you the unique expertise and the experience of a team gathered over the years.

News and next meetings

Presentation at the SMSNA 2023
François Giuliano will present the results of our ongoing studies on "Overview of nonclinical studie......

Presentation at the ICS 2023
"Intravesical administration of EG110A, a novel nonreplicative Herpes Simplex Virus (HSV-1)-derived ......

Presentations at the WCE 2023
Pelvipharm at the 15th World Congress on Endometriosis, May 3rd-6th, 2023. Delphine Behr-Roussel w......

Latest website updates

New abstract/poster available for download

Ex vivo comparison of three BoNT serotypes in the autonomic nervous system and the neuromuscular junction presented at British Pharmacological Society Meeting, Edinburgh, U.K., Dec 17-19 2019, Maignel et al.

New experimental skills developed

Vaginal blood flow engorgement measurement by Laser Doppler Flowmetry (rat/guinea pig/rabbit)

New model developped

Testosterone-supplemented SHR as a model of BPH / male LUTS

TEL +331 704 293 39
FAX + 331 704 295 10